ALK-Abelló

Regulatory Filings • Nov 19, 2010

Summary: ALK launches GRAZAX® in France. GRAZAX® is the first disease-modifying
grass allergy immunotherapy tablet to be introduced in France, the second
largest immunotherapy market in the world.

Today, ALK - the world leader in allergy - announces that the company has
reached an agreement with the French authorities on pricing of the grass
allergy immunotherapy tablet GRAZAX®. With this agreement, GRAZAX® is expected
to be launched and available with reimbursement to French grass allergy
sufferers from January 2011.

GRAZAX® is the first disease-modifying allergy immunotherapy tablet to be
launched in France, the second largest allergy immunotherapy market in the
world and a country with a long-standing tradition for comprehensive sublingual
allergy treatments.

“We are very happy to be able to offer GRAZAX® to the French allergy sufferers.
GRAZAX® is an effective and convenient allergy treatment with documented effect
in both adults and children,” says President and CEO Jens Bager, ALK.

Evidence-based allergy immunotherapy
With the agreement, the French authorities recognise that GRAZAX® is an
improvement compared to the current allergy immunotherapies. GRAZAX® is the
world's first and best documented allergy immunotherapy tablet. 15 randomised
double-blind, placebo-controlled clinical studies have been conducted
demonstrating robust clinical evidence in significant favour of the treatment
and 27 key scientific articles have been published.

“The launch of GRAZAX® is an important step towards converting allergy
treatments to be more evidence-based to the benefit of patients and the
prescribing allergy specialists. With the access of GRAZAX® to the important
French market, we hope to have paved the way for the forthcoming portfolio of
tablets in our pipeline, which also includes tablets against house dust mite,
tree and ragweed pollen allergies. With a portfolio of tablets covering the
most common allergies, we will be able to effectively treat more than 75% of
patients eligible to immunotherapy,” says Jens Bager.

With the introduction of GRAZAX® in France, the treatment is now available with
reimbursement in all major European countries. This announcement does not
change ALK's financial outlook for 2010.

ALK-Abelló A/S

Jens Bager, President and CEO

Contacts: Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
treatment, prevention and diagnosis. ALK is the world leader in allergy
vaccination (immunotherapy). The company has 1,700 employees with subsidiaries,
production facilities and distributors worldwide. ALK is also part of a
strategic partnership with Merck on tablet-based allergy vaccination in North
America. The company is headquartered in Hørsholm, Denmark, and is listed on
NASDAQ OMX Copenhagen A/S. Read more at www.alk-abello.com.